Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

China · Delayed Price · Currency is CNY

25.65

-0.03 (-0.12%)

Sep 30, 2026, 4:00 PM EDT

Market Cap	1.42B -8.5%
Revenue (ttm)	156.77M -24.6%
Net Income	-66.27M
EPS	-1.23
Shares Out	55.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.17 (0.66%)
Ex-Dividend Date	Oct 24, 2025

Volume	984,790
Open	25.41
Previous Close	25.68
Day's Range	25.16 - 25.86
52-Week Range	17.81 - 33.27
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:688217

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addi... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 327

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688217

Full Company Profile

Financial Performance

In 2025, SHA:688217's revenue was 177.26 million, a decrease of -26.84% compared to the previous year's 242.31 million. Losses were -50.38 million, 219.6% more than in 2024.

Financial Statements